UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 30, 2014

 

 

MIRATI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-35921

 

46-2693615

(State of incorporation)

 

(Commission File No.)

 

(IRS Employer Identification No.)

 

9363 Towne Centre Drive, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (858) 332-3410

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.02            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 30, 2014, our Board of Directors, based on the recommendation of our Compensation Committee, approved 2013 incentive cash bonus payments to our executive officers.  The bonus payments were based on an assessment of achievement of corporate goals set out and approved by the Board of Directors in 2013 and were pro-rated for executives that started employment with us during 2013. The 2013 cash bonuses approved for each of our named executive officers were as follows:

 

Name

 

2013 Cash Bonus

 

Charles M. Baum

 

$

280,000

 

Mark J. Gergen

 

$

155,000

 

Isan Chen

 

$

45,000

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 5, 2014

MIRATI THERAPEUTICS, INC.

 

 

 

By:

/s/ Mark J. Gergen

 

 

Mark J. Gergen

 

 

Executive Vice President and Chief Operating Officer

 

3